Antitumor potential of aza-bioisosterism in anthracenedione-based drugs

Current Topics in Medicinal Chemistry

Volumn 4, Issue 2, 2004, Pages 219-230

  Sissi, Claudia ^a   Palumbo, Manlio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 AZA ANTHRACENEDIONE DERIVATIVE; 2 [2 [(2 HYDROXYETHYL)AMINO]ETHYL] 5 [[2 (METHYLAMINO)ETHYL]AMINO]INDAZOLO[4,3 GH]ISOQUINOLIN 6(2H) ONE; 2 AZA ANTHRACENE 9,10 DIONE DERIVATIVE; 2 AZA ANTHRACENEDIONE DERIVATIVE; 9 AZA ANTHRAPYRAZOLE DERIVATIVE; ANTHRAQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; AZA ANTHRAPYRAZOLE DERIVATIVE; BBR 2778; BOSTRYCOIDIN; CLEISTOPHOLINE; DAUNORUBICIN; DIAZA ANTHRACENEDIONE DERIVATIVE; DNA; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ISOPHOMAZARIN; LOSOXANTRONE; MITOXANTRONE; NITROGEN; PHENANTRIDINE DERIVATIVE; PHOMAZARIN; PYRAZOLE DERIVATIVE; SCORPINONE; TOLYPOCLADIN; UNCLASSIFIED DRUG;

ACUTE NONLYMPHOCYTIC LEUKEMIA; ALOPECIA; ANTINEOPLASTIC ACTIVITY; BIOCHEMISTRY; BIOPHYSICS; BLAST CELL CRISIS; BONE MARROW SUPPRESSION; BREAST CANCER; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG DNA BINDING; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG ISOLATION; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; HEART DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKOPENIA; LYMPHOCYTOPENIA; LYMPHOMA; MOLECULAR INTERACTION; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PHYSICAL CHEMISTRY; REVIEW; SKIN DISCOLORATION; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ANIMALS; ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; AZA COMPOUNDS; ESTERS; HUMANS; NEOPLASMS;

EID: 3042654691     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043451483     Document Type: Review

References (61)

1. Lown, J. W. Anthracycline and anthraquinone anticancer agents: current status and recent developments. Pharmacol. Ther. 1993, 60, 185-214.
2. Weiss, R. B. The anthracyclines: will we ever find a better doxorubicin? Semin. Oncol. 1992, 19, 670-686.
3. Bodley, A.; Liu, L. F.; Israel, M.; Seshadri, R.; Koseki, Y.; Giuliani, F. C.; Kirschenbaum, S.; Silber, R.; Potmesil, M. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA. Cancer Res. 1989, 49, 5969-5978.
4. Gille, L.; Nohl, H. Analyses of the molecular mechanism of adriamycin-induced cardiotoxicity. Free Radic. Biol. Med. 1997, 23, 775-782.
5. Horenstein, M. S.; Vander Heide, R. S.; L'Ecuyer, T. J. Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol. Genet. Metab. 2000, 71, 436-444.
6. Bourhis, J.; Riou, G.; Benard, J. Expression of P-glycoprotein 170 (GP 170) and drug resistance in human cancers. Bull Cancer. 1990, 77, 957-965.
7. Arcamone, F. M. From the pigments of the actinomycetes to third generation antitumor anthracyclines. Biochimie 1998, 80, 201-206.
8. Hurteloup, P.; Ganzina, F. Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin. Drugs Exp. Clin. Res. 1986, 12, 233-246.
9. Saletan, S. Mitoxantrone: an active, new antitumor agent with an improved therapeutic index. Cancer Treat. Rev. 1987, 14, 297-303.
10. Weiss, R. B. Mitoxantrone: its development and role in clinical practice. Oncology (Huntingt) 1989, 3, 135-141.
11. Thomas, X.; Archimbaud, E. Mitoxantrone in the treatment of acute myelogenous leukemia: a review. Hematol. Cell. Ther. 1997, 39, 63-74.
12. Burger, A. Isosterism and bioisosterism in drug design. Prog. Drug Res. 1991, 37, 287-371.
13. Olesen, P. H. The use of bioisosteric groups in lead optimization. Curr. Opin. Drug Discov. Devel. 2001, 4, 471-478.
14. Krapcho, A. P.; Maresch, M. J.; Hacker, M. P.; Hazelhurst, L.; Menta, E.; Spinelli, S.; Beggiolin, G.; Giuliani, F. C.; Pezzoni, P; Tognella, S. Anthracene-9,10-diones and aza bioisosteres as antitumor agents. Curr. Med. Chem. 1995, 2, 803-824.
15. Boger, D. L.; Dong, J. Y.; Hikota, M.; Ishida, M. Total synthesis of phomazarin. J. Am. Chem. Soc. 1999, 12, 2471-2477.
16. Seidel, V.; Bailleul, F.; Waterman, P. G. Novel oligorhamnosides from the stem bark of Cleistopholis glauca. J. Nat. Prod. 2000, 63, 6-11.
17. Hsieh, T. J.; Chang, F. R.; Chia, Y. C.; Chen, C. Y.; Chiu, H. F.; Wu, Y. C. Cytotoxic constituents of the fruits of Cananga odorata. J. Nat. Prod. 2001, 64, 616-619.
18. Waterman, P. G.; Muhammad, I. Sesquiterpenes and alkaloids from Cleistopholis patens. Phytochem. 1985, 24, 523-527.
19. Peterson, J. R., Zjawiony, J. K., Liu, S. C., Hufford, C. D.; Clark, A. M.; Rogers, R. D. Copyrine alkaloids - synthesis, spectroscopic characterization, and antimycotic - antimycobacterial activity of A-ring-functionalized and B-ring-functionalized Sampangines. J. Med. Chem. 1992, 35, 4069-4077.
20. Chaves, M. H.; Santos, L. D.; Lago, J. H. G.; Roque, N. F. Alkaloids from Porcelia macrocarpa. J. Nat. Prod. 2001, 64, 240-242.
21. Gore, M. P.; Gould, S. J.; Weller; D. D. Total synthesis of phenanthroviridin aglycon - The 1st naturally-occurring benzo[b]phenanthridine. J. Org. Chem. 1991, 56, 2289-2291.
22. Cone, M. C.; Hassan, A. M.; Gore, M. P.; Gould, S. J.; Bordens, D. B.; Alluri, M. R. Detection of phenanthroviridin aglycone in a uv-mutant of Streptomyces-murayamaensis. J. Org. Chem. 1994, 59, 1923-1924.
23. Parisot, D.; Devys, M.; Barbier, M. Conversion of anhydrofusarubin lactol into the antibiotic bostrycoidin. J. Antibiot. (Tokyo) 1989, 42, 1189-1190.
24. Parisot, D.; Devys, M.; Barbier, M. 6-O-demethyl-5-deoxybostrycoidin, a 2-aza-anthraquinone produced by the fungus Nectria-haematococca. Phytochem. 1990, 29, 3364-3365.
25. Krapcho, A. P.; Waterhouse, D. J. General synthetic pathway to oxygenated 3-methylbenz[g]isoquinoline-5,10-diones. Heterocycles 1999, 51,737-750.
26. Kesteleyn, B.; De Kimpe, N. Synthesis of two naphthoquinone antibiotics, dehydroherbarin and 6-deoxybostrycoidin. J. Org. Chem. 2000, 65, 640-644.
27. Kesteleyn, B.; Van, T. N.; De Kimpe, N. Synthesis of 3-Alkyl- and 3-aryl-2-aza-anthraquinones. Tetrahedron 1999, 55, 2091-2102.
28. Deshpande, V. H.; Khan, R. A.; Ayyangar, N. R. Regiospecific synthesis of bostrycoidin. Indian J. Chem. B 1996, 35, 965-966.
29. Moriyasu, Y.; Miyagawa, H.; Hamada, N.; Miyawaki, H.; Ueno, T. Synthetic pathways 5-deoxy-7-methylbostrycoidin from cultured mycobionts from Haematomma sp. Phytochem. 2001, 58, 239-241.
30. Yamamoto, Y.; Kinoshita, Y.; Ran T. G.; Hasumi, M.; Kinoshita, K.; Koyama, K.; Takahashi, K.; Yoshimura, I. Isofuranonaphthoquinone derivatives from cultures of the lichen Arthonia cinnabarina (DC.) Wallr. Phytochem. 2002, 60, 741-745.
31. Miljkovic, A.; Mantle, P. G.; Williams, D. J.; Rassing, B. Scorpinone: a new natural azaanthraquinone produced by a Bispora-like tropical fungus. J. Nat. Prod. 2001, 64, 1251-1253.
32. Burckhardt, G.; Walter, A.; Triebel, H.; Storl, K.; Simon, H.; Storl, J.; Opitz, A.; Roemer, E.; Zimmer, C. Binding of 2-azaanthraquinone derivatives to DNA and their interference with the activity of DNA topoisomerases in vitro. Biochemistry 1998, 37, 4703-4711.
33. Krapcho, A. P.; Landi, J. J. Jr.; Hacker, M. P.; McCormack, J. J. Synthesis and antineoplastic evaluations of 5,8-bis[(aminoalkyl)amino]-1-azaanthracene-9,10-diones. J. Med. Chem. 1985, 28, 1124-1126.
34. Krapcho, A. P.; Petry, M. E.; Getahun, Z.; Landi, J. J. Jr.; Stallman, J.; Polsenberg, J. F.; Gallagher, C. E.; Maresch, M. J.; Hacker, M. P.; Giuliani, F. C.; Beggiolin, G.; Pezzoni, G.; Menta, E.; Manzotti, C.; Oliva, A.; Spinelli, S.; Tognella, S. 6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations. J. Med. Chem. 1994, 37, 828-837.
35. Krapcho, A. P.; Maresch, M. J.; Gallagher, C. E.; Hacker, M. P. Synthesis of 4-hydroxy-6,9-difluorobenz[g]isoquinoline-5,10-diones and conversions to 4-hydroxy-6,9-bis[(aminoalkyl)amino]-benz[g]isoquinoline-5,10-diones J. Heterocyclic Chem. 1995, 32, 1693-1702.
36. Krapcho, A. P.; Maresch, M. J.; Helgason, A. L.; Rosner, K. E.; Hacker, M. P.; Spinelli, S.; Menta, E.; Oliva, A.; Di Domenico, R. The synthesis of 6,9-bis[(aminoalkyl)amino]substituted benzo[g]quinoxaline-5,10-diones, benzo[g]quinazoline-5,10-diones and benzo-[g]phthalazine-5,10-diones via regiospecific displacements. J. Heterocyclic Chem. 1993, 30, 1597-1606.
37. Gandolfi, C. A.; Beggiolin, G.; Menta, E.; Palumbo, M.; Sissi, C.; Spinelli, S., Johnson, F. Chromophore-modified antitumor anthracenediones: synthesis, DNA binding, and cytotoxic activity of 1,4-bis[(aminoalkyl)amino]benzo[g]-phthalazine-5,10-diones. J. Med. Chem. 1995, 38, 526-536.
38. Hazlehurst, L. A.; Krapcho, A. P.; Hacker, M. P. Correlation of DNA reactivity and cytotoxicity of a new class of anticancer agents: aza-anthracenediones. Cancer Lett. 1995, 91, 115-124.
39. Sissi, C.; Palumbo, M., unpublished results.
40. De Isabella, P.; Palumbo, M.; Sissi, C.; Capranico, G.; Carenini, N.; Menta, E.; Oliva, A.; Spinelli, S.; Krapcho, A. P.; Giuliani, F. C.; Zunino, F. Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives. Mol. Pharmacol. 1995, 48, 30-38.
41. Hazlehurst, L. A.; Krapcho, A. P.; Hacker, M. P. Comparison of aza-anthracenedione-induced DNA damage and cytotoxicity in experimental tumor cells. Biochem Pharmacol. 1995, 50,1087-1094.
42. Sissi, C.; Moro, S.; Zagotto, G.; Ellis, M.; Krapcho, A. P.; Menta, E.; Palumbo, M. Binding of bis-substituted 2-aza-anthracenedione regioisomers to DNA: effects of the relative positioning of the side chains. Anticancer Drug Des. 1999, 14, 265-274.
43. Tarasiuk, J.; Tkaczyk Gobis, K.; Stefanska, B.; Dzieduszycka, M.; Priebe, W.; Martelli, S.; Borowski, E. The role of structural factors of anthraquinone compounds and their quinone-modified analogues in NADH dehydrogenase-catalysed oxygen radical formation. Anticancer Drug Des. 1998, 13, 923-939.
44. Lown, J. W.; Morgan, A. R.; Yen, S. F.; Wang, Y. H.; Wilson, W. D. Characteristics of the binding of the anticancer agents mitoxantrone and ametantrone and related structures to deoxyribonucleic acids. Biochemistry 1985, 24, 4028-4035.
45. Zwelling, L. A.; Mayes, J.; Altschuler, E.; Satitpunwaycha, P.; Tritton, T. R.; Hacker, M. P. Activity of two novel anthracene-9,10-diones against human leukemia cells containing intercalator-sensitive or -resistant forms of topoisomerase II. Biochem. Pharmacol. 1993, 46, 265-271.
46. Chou, K. M.; Krapcho, A. P.; Horn, D.; Hacker, M. P. Characterization of anthracenediones and their photoaffinity analogs. Biochem. Pharmacol. 2002, 63, 1143-1147.
47. De Isabella, P.; Palumbo, M.; Sissi, C.; Carenini, N.; Capranico, G.; Menta, E.; Oliva, A.; Spinelli, S., Krapcho, A. P.; Giuliani, F. C.; Zunino, F. Physicochemical properties, cytotoxic activity and topoisomerase II inhibition of 2,3-diaza-anthracenediones. Biochem. Pharmacol. 1997, 53, 161-169.
48. Sissi, C.; Capranico, G.; Menta, E.; Palumbo, M. Aza-bioisosteres of 9,10-anthracenedione: A modulation of DNA sequence specificity. Mol. Pharmacol. 1996, 50, 838-845.
49. Beggiolin, G.; Crippa, L.; Menta, E.; Manzotti, C.; Cavalletti, E.; Pezzoni, G.; Torrioni, D.; Randisi, E.; Cavagnoli, R.; Sala, F.; Giuliani, F.C.; Spinelli, S. BBR 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Tumori 2001, 87, 407-416.
50. Faivre, S.; Raymond, E.; Boige, V.; Gatineau, M.; Buthaut, X.; Rixe, O.; Bernareggi, A.; Camboni, G.; Armand, J. P. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies. Clin. Cancer Res. 2001, 7, 43-50.
51. Borchmann, P.; Schnell, R.; Knippertz, R.; Staak, J. O.; Camboni, G. M.; Bernareggi, A.; Hubel, K.; Staib, P.; Schulz, A.; Diehl, V.; Engert, A. Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. Ann. Oncol. 2001, 12, 661-667.
52. Krapcho, A. P.; Menta, E. Antitumor aza-anthrapyrazoles. Drugs Fut. 1997, 22, 641-646.
53. Judson, I. R. The anthrapyrazoles: a new class of compounds with clinical activity in breast cancer. Semin. Oncol. 1992, 19, 687-694.
54. Talbot, D. C.; Smith, I. E.; Mansi, J. L.; Judson, I.; Calvert, A. H.; Ashley, S. E. Anthrapyrazole CI941: a highly active new agent in the treatment of advanced breast cancer. J. Clin. Oncol. 1991, 9, 2141-2147.
55. Walsh, S. M.; Walley, V. M.; Chandra, L.; Huan, S. D.; Veinot, J. P.; Higginson, L. A. J. Potential cardiotoxicity with the use of DuP-941: A case report. Can. J. Cardiol. 1995, 11, 419-422.
56. Krapcho, A. P.; Menta, E.; Oliva, A.; Di Domenico, R.; Fiocchi, L.; Maresch, M. E.; Gallagher, C. E.; Hacker, M. P.; Beggiolin, G.; Giuliani, F. C.; Pezzoni, G.; Spinelli, S. Synthesis and antitumor evaluation of 2,5-disubstituted-indazolo[4,3-gh]isoquinolin-6(2H)-ones (9-aza-anthrapyrazoles). J. Med. Chem. 1998, 41, 5429-5444.
57. Chou, K. M.; Krapcho, A. P.; Hacker, M. P. Impact of the basic amine on the biological activity and intracellular distribution of an aza-anthrapyrazole: BBR 3422. Biochem. Pharmacol. 2001, 62, 1337-1343.
58. Sissi, C.; Moro, S.; Richter, S.; Gatto, B.; Menta, E.; Spinelli, S.; Krapcho, A. P.; Zunino, F.; Palumbo, M. DNA-interactive anticancer aza-anthrapyrazoles: biophysical and biochemical studies relevant to the mechanism of action. Mol. Pharmacol. 2001, 59, 96-103.
59. Hartley, J. A.; Reszka, K.; Zuo, E. T.; Wilson, W. D.; Morgan, A. R.; Lown, J. W. Characteristics of the interaction of anthrapyrazole anticancer agents with deoxyribonucleic acids: structural requirements for DNA binding, intercalation, and photosensitization. Mol. Pharmacol. 1988, 33, 265-271.
60. Krapcho, A. P.; Gallagher, C. E.; Hammach, A.; Hacker, M. P.; Menta, E.; Oliva, A.; Di Domenico, R.; Da Re, G.; Lotto, A.; Spinelli, S. Synthesis of hydroxy-substituted aza-analogues of antitumor anthrapyrazoles. J. Heterocyclic Chem. 1998, 35, 895-906.
61. Supino, R.; Polizzi, D.; Pavesi, R.; Pratesi, G.; Guano, F.; Capranico, G.; Palumbo, M.; Sissi, C.; Richter, S.; Beggiolin, G.; Menta, E.; Pezzoni, G.; Spinelli, S.; Torrioni, D.; Carenini, N.; Dal Bo, L.; Facchinetti, F.; Tortereto, M.; Zumino, F. A novel 9-aza-anthrapyrazole effective against human prostatic carcinoma xenografts. Oncology 2001, 61, 234-242.